Edwards Lifesciences Corporation (EW)
NYSE: EW · Real-Time Price · USD
89.72
+0.40 (0.45%)
Aug 7, 2026, 4:00 PM EDT - Market closed

Edwards Lifesciences Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
6,5126,0685,4405,0104,4645,233
Revenue Growth
14.55%11.55%8.57%12.23%-14.69%19.29%
Gross Profit
5,0694,7334,3224,0323,7403,984
Operating Income
1,4491,2641,3791,3091,4981,690
Net Income
1,0051,0744,1751,4021,5221,503
Earnings Per Share
1.741.836.972.302.442.38
EPS Growth
-74.96%-73.75%203.04%-5.74%2.52%83.08%

Revenue by Segment

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Transcatheter Aortic Valve Replacement
4,7664,4884,1063,8803,5183,423
Transcatheter Mitral and Tricuspid Therapies
674.6550.6352.1197.6116.186
Surgical Structural Heart
1,0721,029981.3932.6829.7889.1
Revenue (Total)
6,5126,0685,4405,0104,4645,233

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
4,2534,2263,9761,6331,2151,467
Total Debt
704.4705.4700685.1691.3690.3
Net Cash (Debt)
3,5483,5213,276947.7524776.5
Net Cash Growth
5.62%7.48%245.67%80.86%-32.52%9.72%
Net Cash Per Share
6.106.015.471.560.841.23

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
1,7201,595542.3895.81,2181,732
Capital Expenditures
-286.7-260.2-252.4-253-244.6-325.8
Free Cash Flow
1,4341,335289.9642.8973.61,406
Free Cash Flow Growth
143.85%360.50%-54.90%-33.98%-30.77%117.26%

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
77.84%78.01%79.46%80.47%83.79%76.13%
Operating Margin
22.25%20.84%25.35%26.13%33.57%32.30%
Pretax Margin
21.77%20.98%28.46%27.39%34.04%32.53%
Profit Margin
15.03%17.40%25.66%24.35%29.66%28.73%
FCF Margin
22.01%22.00%5.33%12.83%21.81%26.88%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
53.5346.5810.6233.1530.5854.43
Forward PE
28.5830.9331.1928.4130.3552.98
P/FCF Ratio
36.0737.08150.3171.3046.6257.49
PS Ratio
7.948.168.019.1510.1715.45